- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Denver, Colorado
- Conditions
- Atopic Dermatitis
- Interventions
- GIA632, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Fremont, California • Rockville, Maryland • Hoboken, New Jersey
- Conditions
- Long QT Syndrome
- Interventions
- Simplified Cascade Screening
- Genetic
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- Not listed
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Not listed
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 27
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 22 more
- Conditions
- Tic Disorders, Tics, Tic, Motor, Tic Disorder, Childhood, Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
- Interventions
- Comprehensive Behavioral Intervention for Tics (CBIT), Repetitive Transcranial Magnetic Stimulation (rTMS), Continuous Theta Burst Stimulation (cTBS)
- Behavioral · Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cystic Fibrosis
- Interventions
- Human recombinant growth hormone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 5 Years to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Houston, Texas • Salt Lake City, Utah
- Conditions
- Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Ovarian Cancer
- Interventions
- Tuvusertib (M1774), Niraparib, Lartesertib (M4076)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more
- Conditions
- Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
- Conditions
- Fetal Alcohol Spectrum Disorders
- Interventions
- Families Moving Forward (FMF) Teacher adapted training
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Rett Syndrome
- Interventions
- Not listed
- Lead sponsor
- Rett Syndrome Research Trust
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Advanced Unresectable Melanoma, Metastatic Melanoma
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- Kevin Kim, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Burns, Skin Graft Complications, Skin; Deformity
- Interventions
- Suprathel or Xeroform donor site application
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Acute Pain, Bunion, Abdominoplasty
- Interventions
- Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg
- Drug
- Lead sponsor
- iX Biopharma Ltd.
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- DSAEK with graft shaping and smoothing, Standard DSAEK
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Rapamycin, Standard of Care-Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Spinocerebellar Ataxia
- Interventions
- Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tourette Syndrome
- Interventions
- transcranial magnetic stimulation
- Device
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Administration of drug (Interferon-gamma 1-b) subcutaneously
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease
- Interventions
- [18F]-FEOBV Radiotracer
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
- Interventions
- gemtuzumab ozogamicin, vorinostat, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 4
- States / cities
- Stanford, California • Detroit, Michigan • Winston-Salem, North Carolina + 1 more
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, Fludarabine, Melphalan, Stem Cells
- Drug · Procedure
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Dyskeratosis Congenita, Telomere Disease
- Interventions
- Quercetin
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio